Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GLP1R | P43220 | 8/20 | 0.39 |
| ▸ | POLB | P06746 | 1/20 | 0.33 |
| ▸ | TLR2 | O60603 | 2/20 | 0.32 |
| ▸ | PLG | P00747 | 2/20 | 0.31 |
| ▸ | PRSS1 | P07477 | 2/20 | 0.31 |
| ▸ | PRSS2 | P07478 | 2/20 | 0.31 |
| ▸ | PRSS3 | P35030 | 2/20 | 0.31 |
| ▸ | PLAU | P00749 | 1/20 | 0.31 |
| ▸ | LPAR3 | Q9UBY5 | 2/20 | 0.31 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.31 |
| ▸ | SYK | P43405 | 1/20 | 0.30 |
| ▸ | CHRNA1 | P02708 | 1/20 | 0.30 |
| ▸ | CHRNG | P07510 | 1/20 | 0.30 |
| ▸ | CHRNB1 | P11230 | 1/20 | 0.30 |
| ▸ | CHRND | Q07001 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24264671 | 0.95 | GLP1R (0.43) | GLP1RPOLBTLR2PLGPRSS1 | |
| SCHEMBL23869978 | 0.95 | GLP1R (0.43) | GLP1RPOLBTLR2PLGPRSS1 | |
| SCHEMBL22452901 | 0.92 | GLP1R (0.39) | GLP1RPOLBTLR2PLGPRSS1 | |
| SCHEMBL24123483 | 0.91 | GLP1R (0.38) | GLP1RPOLBTLR2PLGPRSS1 | |
| SCHEMBL24123485 | 0.91 | GLP1R (0.39) | GLP1RPOLBPLGPRSS1PRSS2 | |
| SCHEMBL20375531 | 0.86 | GLP1R (0.43) | GLP1RPOLBTLR2PLGPRSS1 | |
| SCHEMBL18715377 | 0.86 | GLP1R (0.43) | GLP1RPOLBTLR2PLGPRSS1 | |
| SCHEMBL24479569 | 0.86 | GLP1R (0.43) | GLP1RPOLBTLR2PLGPRSS1 | |
| SCHEMBL18715404 | 0.86 | GLP1R (0.43) | GLP1RPOLBTLR2PLGPRSS1 | |
| SCHEMBL23870009 | 0.85 | GLP1R (0.43) | GLP1RPOLBPLGPRSS1PRSS2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230323350-A1 | RNAi Agents And Compositions for Inhibiting Expression of Apolipoprotein C-III (APOC3) | SIXTH STREETLENDING PARTNERS, AS THE ADMINISTRATIVE AGENT | 2023-10-12 | — | — | US | disclosed |
| US-11214801-B2 | RNAi agents and compositions for inhibiting expression of apolipoprotein C-III (APOC3) | Arrowhead Pharmaceuticals, Inc. (US) | 2022-01-04 | — | — | US | disclosed |
| US-20200299690-A1 | RNAi Agents And Compositions for Inhibiting Expression of Apolipoprotein C-III (APOC3) | SIXTH STREETLENDING PARTNERS, AS THE ADMINISTRATIVE AGENT | 2020-09-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11214801-B2 | RNAi agents and compositions for inhibiting expression of apolipoprotein C-III (APOC3) | APOB, LDLR, APOL1 | GLP1R 2229/4885POLB 2356/4885TLR2 2801/4885 |
| US-20200299690-A1 | RNAi Agents And Compositions for Inhibiting Expression of Apolipoprotein C-III (APOC3) | APOB, LDLR, APOL1 | GLP1R 2229/4885POLB 2356/4885TLR2 2801/4885 |
| US-20230323350-A1 | RNAi Agents And Compositions for Inhibiting Expression of Apolipoprotein C-III (APOC3) | APOB, LDLR, APOL1 | GLP1R 2229/4885POLB 2356/4885TLR2 2801/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.